Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q9)Sep 30, 2025 | (Q6)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | -6.12%7.06B | 0.75%4.65B | 9.41%2.34B | 20.91%10.32B | 20.92%7.53B | 10.73%4.61B | 8.45%2.14B | 11.74%8.53B | 12.66%6.22B | 12.93%4.16B |
| Operating income | -6.12%7.06B | 0.75%4.65B | 9.41%2.34B | 20.91%10.32B | 20.92%7.53B | 10.73%4.61B | 8.45%2.14B | 11.74%8.53B | 12.66%6.22B | 12.93%4.16B |
| Cost of sales | -4.67%-1.35B | -5.46%-873.19M | -5.85%-419.41M | -15.58%-1.74B | -18.26%-1.29B | -17.18%-827.95M | -14.88%-396.22M | -2.98%-1.5B | -0.11%-1.09B | 1.48%-706.56M |
| Operating expenses | -4.67%-1.35B | -5.46%-873.19M | -5.85%-419.41M | -15.58%-1.74B | -18.26%-1.29B | -17.18%-827.95M | -14.88%-396.22M | -2.98%-1.5B | -0.11%-1.09B | 1.48%-706.56M |
| Gross profit | -8.35%5.72B | -0.28%3.77B | 10.22%1.92B | 22.05%8.58B | 21.48%6.24B | 9.41%3.78B | 7.09%1.74B | 13.81%7.03B | 15.73%5.13B | 16.41%3.46B |
| Selling expenses | -32.15%-1.33B | -19.32%-764.5M | -30.30%-340.47M | 8.47%-1.35B | 8.02%-1.01B | 1.76%-640.7M | 25.59%-261.29M | -18.35%-1.47B | -20.45%-1.09B | -18.15%-652.2M |
| Administrative expenses | -6.28%-511.82M | -5.80%-333.93M | -0.01%-160.29M | 4.10%-634.3M | 1.78%-481.59M | -4.11%-315.63M | -7.00%-160.27M | -6.86%-661.43M | -7.41%-490.3M | -0.93%-303.16M |
| Research and development expenses | -11.50%-2.58B | -15.65%-1.68B | -16.14%-827.85M | -13.48%-3.05B | -15.83%-2.31B | -9.60%-1.45B | -7.83%-712.79M | -5.13%-2.68B | -5.63%-2B | -6.09%-1.33B |
| Special items of operating profit | -131.75%-33.28M | -134.63%-8.07M | 343.03%11.48M | 660.82%91.75M | 363.51%104.8M | 159.52%23.3M | -52.82%-4.72M | -88.61%12.06M | -156.71%-39.77M | -176.56%-39.15M |
| Operating profit | -50.35%1.26B | -29.49%984.11M | -0.02%601.45M | 63.75%3.65B | 67.96%2.54B | 22.85%1.4B | 30.69%601.58M | 19.17%2.23B | 20.97%1.51B | 23.72%1.14B |
| Financing income | -2.72%520.54M | 0.58%353.18M | -0.48%187.68M | 14.52%720.58M | 18.89%535.08M | 28.14%351.15M | 39.87%188.58M | 40.13%629.2M | 35.84%450.07M | 22.11%274.03M |
| Financing cost | 57.88%-55.92M | 38.48%-54.35M | -2.97%-44.89M | -5.78%-178.66M | -5.74%-132.75M | -7.11%-88.33M | -6.96%-43.6M | -7.27%-168.89M | -8.75%-125.54M | -9.11%-82.47M |
| Share of profits of associates | 58.43%-318.22M | 4.46%-322.83M | 9.48%-152.72M | 20.28%-913.8M | 11.04%-765.48M | 38.96%-337.91M | 26.88%-168.72M | 15.85%-1.15B | 22.24%-860.47M | 20.05%-553.56M |
| Share of profit from joint venture company | -23.71%-30.27M | -32.23%-19.97M | -28.23%-12.33M | 151.50%10.27M | -138.23%-24.47M | -162.47%-15.1M | -152.43%-9.62M | -1.58%-19.95M | -55.79%-10.27M | -123.59%-5.75M |
| Special items of earning before tax | 641.31%433.42M | 2,636.71%420.56M | -417.67%-22.29M | -378.14%-153.77M | -97.48%-80.07M | 71.73%-16.58M | -109.78%-4.31M | 99.51%-32.16M | 99.37%-40.55M | -303.66%-58.65M |
| Earning before tax | -12.62%1.81B | 5.58%1.36B | -1.25%556.9M | 110.31%3.13B | 123.92%2.07B | 81.63%1.29B | 54.99%563.92M | 126.02%1.49B | 115.16%925.34M | 77.02%709.61M |
| Tax | -79.49%-218.87M | -68.22%-152.58M | -14.17%-48.33M | -22.11%-334.16M | 17.45%-121.94M | 12.68%-90.71M | -63.44%-42.34M | -172.12%-273.66M | -128.20%-147.71M | -60.01%-103.88M |
| After-tax profit from continuing operations | -18.38%1.59B | 0.83%1.21B | -2.50%508.56M | 130.18%2.8B | 150.78%1.95B | 97.80%1.2B | 54.34%521.59M | 122.75%1.22B | 113.93%777.63M | 80.31%605.73M |
| Earning after tax | -18.38%1.59B | 0.83%1.21B | -2.50%508.56M | 130.18%2.8B | 150.78%1.95B | 97.80%1.2B | 54.34%521.59M | 122.75%1.22B | 113.93%777.63M | 80.31%605.73M |
| Minority profit | -34.53%562.26M | -24.68%391.81M | -5.20%224.69M | 70.21%1.25B | 71.88%858.74M | 46.05%520.21M | 62.78%237.02M | 3.42%731.73M | -3.10%499.61M | -5.77%356.2M |
| Profit attributable to shareholders | -5.68%1.03B | 20.41%816.31M | -0.24%283.87M | 220.94%1.55B | 292.55%1.09B | 171.68%677.92M | 47.95%284.57M | 107.99%483.46M | 104.56%278.02M | 693.22%249.53M |
| Basic earnings per share | -8.54%0.75 | 17.65%0.6 | 0.00%0.21 | 222.22%1.16 | 310.00%0.82 | 183.33%0.51 | 50.00%0.21 | 108.13%0.36 | 104.47%0.2 | 700.00%0.18 |
| Diluted earnings per share | -5.13%0.74 | 20.41%0.59 | 0.00%0.21 | 226.47%1.11 | 310.53%0.78 | 188.24%0.49 | 50.00%0.21 | 107.64%0.34 | 104.23%0.19 | 440.00%0.17 |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- | -- |
| Auditor | -- | -- | -- | Ernst & Young Accounting Firm | -- | -- | -- | Ernst & Young Accounting Firm | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.